Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
暂无分享,去创建一个
P. Wee | Zhixiang Wang | Zhixiang Wang | Ping Wee | Ping Wee
[1] J Downward,et al. Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. , 1994, The Journal of biological chemistry.
[2] Y. Maehara,et al. Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] Masato Okada,et al. Regulation of the Src Family Kinases by Csk , 2012, International journal of biological sciences.
[4] Spyro Mousses,et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.
[5] Yukiko Nakamura,et al. Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports , 2011, Cancer science.
[6] J. Brugge,et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.
[7] M. Vijjeswarapu,et al. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells , 2010, The Journal of Steroid Biochemistry and Molecular Biology.
[8] J. Blenis,et al. Characterization of Regulatory Events Associated with Membrane Targeting of p90 Ribosomal S6 Kinase 1 , 2001, Molecular and Cellular Biology.
[9] P. Rous. A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS , 1911, The Journal of experimental medicine.
[10] Walter Kolch,et al. Untying the regulation of the Raf-1 kinase. , 2002, Archives of biochemistry and biophysics.
[11] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[12] A. Lièvre,et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Ruchti,et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. , 2001, Thyroid : official journal of the American Thyroid Association.
[14] Stanley N. Cohen. Origins of Growth Factors: NGF and EGF , 2004, Annals of the New York Academy of Sciences.
[15] Geoffrey R. Oxnard,et al. Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.
[16] Benjamin G. Bitler,et al. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor , 2010, Journal of Cell Science.
[17] T. Mitsudomi,et al. Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. , 2009, Lung cancer.
[18] P. Seeburg,et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.
[19] P. Cohen,et al. Identification of Regulatory Phosphorylation Sites in Mitogen-activated Protein Kinase (MAPK)-activated Protein Kinase-1a/p90 rsk That Are Inducible by MAPK* , 1998, The Journal of Biological Chemistry.
[20] Sarat Chandarlapaty,et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.
[21] L. Fu,et al. Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. , 2014, American journal of cancer research.
[22] L. Cantley,et al. Phosphoinositide 3-kinase in immunological systems. , 2002, Seminars in immunology.
[23] J. Petrik,et al. Opposing Functions of Akt Isoforms in Lung Tumor Initiation and Progression , 2014, PloS one.
[24] J. B. Park,et al. Phosphorylation and activation of phospholipase D1 by protein kinase C in vivo: determination of multiple phosphorylation sites. , 1999, Biochemistry.
[25] A. King,et al. correction: The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338 , 2000, Nature.
[26] V. Band,et al. Tyrosine Phosphorylation of Cbl upon Epidermal Growth Factor (EGF) Stimulation and Its Association with EGF Receptor and Downstream Signaling Proteins* , 1996, The Journal of Biological Chemistry.
[27] K. O'Byrne,et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. , 2016, The Lancet. Oncology.
[28] M. Waterfield,et al. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. , 1986, Cancer research.
[29] Y. Katayama,et al. Protein kinase C (PKC) isozyme-specific substrates and their design. , 2012, Biotechnology advances.
[30] A. Ullrich,et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.
[31] P. Heinrich,et al. Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. , 2001, The Biochemical journal.
[32] P. Seth,et al. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. , 1997, Cancer research.
[33] J. Blenis,et al. MAPK signal specificity: the right place at the right time. , 2006, Trends in biochemical sciences.
[34] A. N. Meyer,et al. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. , 2000, Molecular biology of the cell.
[35] A. Alavi,et al. Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.
[36] R. Abraham. mTOR as a positive regulator of tumor cell responses to hypoxia. , 2004, Current topics in microbiology and immunology.
[37] J. Cheng,et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[38] Y. Yarden,et al. Src promotes destruction of c-Cbl: Implications for oncogenic synergy between Src and growth factor receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] M. H. Cobb,et al. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338 , 2000, Current Biology.
[40] G. Carpenter,et al. Increase of the catalytic activity of phospholipase C-gamma 1 by tyrosine phosphorylation. , 1990, Science.
[41] E. Van Cutsem,et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] M. Hung,et al. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. , 2005, Cancer research.
[43] J. Weber,et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases , 1997, Nature.
[44] Stuart Thomson,et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.
[45] L. Cantley,et al. Purification and characterization of phosphoinositide 3-kinase from rat liver. , 1990, The Journal of biological chemistry.
[46] D. W. Fry,et al. G1 cell cycle arrest due to the inhibition of erbB family receptor tyrosine kinases does not require the retinoblastoma protein. , 2004, Experimental cell research.
[47] Chi V Dang,et al. MYC on the Path to Cancer , 2012, Cell.
[48] A. Newton,et al. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. , 2007, Molecular cell.
[49] D. Tindall,et al. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line , 1998, The Prostate.
[50] John Foley,et al. Functional selectivity of EGF family peptide growth factors: implications for cancer. , 2009, Pharmacology & therapeutics.
[51] Borivoj Vojnovic,et al. Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer , 2014, Science Signaling.
[52] M. Hung,et al. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival , 2006, British Journal of Cancer.
[53] P. Bork,et al. Epidermal growth factor-like modules , 1993 .
[54] M. Beato,et al. Inducible regulatory elements in the human cyclin D1 promoter. , 1994, Oncogene.
[55] K. Inoki,et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.
[56] J. Hazle,et al. The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis , 2012, Cell.
[57] M. Sliwkowski,et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.
[58] T. Pawson,et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction , 1992, Cell.
[59] Paul Shapiro,et al. Cross‐cascade activation of ERKs and ternary complex factors by Rho family proteins , 1997, The EMBO journal.
[60] D. Rouillard,et al. Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro , 2004, British Journal of Cancer.
[61] J. Ihle,et al. Absence of Erythrogenesis and Vasculogenesis in Plcg1-deficient Mice* , 2002, The Journal of Biological Chemistry.
[62] D. Gomes,et al. Epidermal growth factor receptors destined for the nucleus are internalized via a clathrin-dependent pathway. , 2011, Biochemical and biophysical research communications.
[63] P. Bastiaens,et al. EGF-dependent re-routing of vesicular recycling switches spontaneous phosphorylation suppression to EGFR signaling , 2015, eLife.
[64] Kuo-Fen Lee,et al. Rescue of the Cardiac Defect in ErbB2 Mutant Mice Reveals Essential Roles of ErbB2 in Peripheral Nervous System Development , 1999, Neuron.
[65] T. Bekaii-Saab,et al. Integrating anti-EGFR therapies in metastatic colorectal cancer. , 2013, Journal of gastrointestinal oncology.
[66] Stephanie M. Tortorella,et al. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K , 2015, Molecular Biology Reports.
[67] Tarun B Patel,et al. A historical perspective of the EGF receptor and related systems. , 2006, Methods in molecular biology.
[68] Monilola A. Olayioye,et al. ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases* , 1999, The Journal of Biological Chemistry.
[69] N. Malek,et al. p27kip1: a target for tumor therapies? , 2007, Cell Division.
[70] G. Cooper,et al. A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells , 2011, Cell cycle.
[71] I. Pastan,et al. A transcription factor active on the epidermal growth factor receptor gene. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[72] Julian Downward,et al. Epidermal growth factor regulates p21 ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor , 1993, Cell.
[73] M. Maa,et al. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[74] N. Normanno,et al. Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.
[75] L. Schwartz,et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] S. Choi,et al. Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma , 2008, Clinical Cancer Research.
[77] Paul Tempst,et al. Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.
[78] S. Iacobelli,et al. Phospholipase Cgamma1 is required for metastasis development and progression. , 2008, Cancer research.
[79] Tony Pawson,et al. Specificity in Signal Transduction From Phosphotyrosine-SH2 Domain Interactions to Complex Cellular Systems , 2004, Cell.
[80] John Kuriyan,et al. The structural basis of the activation of Ras by Sos , 1998, Nature.
[81] J. Woodgett,et al. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. , 1994, The Biochemical journal.
[82] I. Lax,et al. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway , 2004, BMC Biology.
[83] I. Pastan,et al. Epidermal growth factor regulates the expression of its own receptor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[84] M. Eilers,et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter , 2003, Oncogene.
[85] T. Golub,et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. , 2006, Cancer research.
[86] Robert J Coffey,et al. EGF receptor ligands. , 2003, Experimental cell research.
[87] S. Staal. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[88] T Pawson,et al. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. , 1994, Oncogene.
[89] K. Herrup,et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.
[90] John Calvin Reed,et al. Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.
[91] T. Pawson,et al. How is SOS activated? Let us count the ways , 2008, Nature Structural &Molecular Biology.
[92] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[93] G. Todaro,et al. Growth factors from murine sarcoma virus-transformed cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[94] N. Ahn,et al. Signal transduction through MAP kinase cascades. , 1998, Advances in cancer research.
[95] M. Sliwkowski,et al. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[96] Yulei N. Wang,et al. A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition , 2014, The Biochemical journal.
[97] G. Cavet,et al. Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients , 2005, Clinical Cancer Research.
[98] E. Van Cutsem,et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] S. Sigismund,et al. Chapter Six - The Ubiquitin Network in the Control of EGFR Endocytosis and Signaling. , 2016, Progress in molecular biology and translational science.
[100] J. D. Zieske,et al. Regional variation in distribution of EGF receptor in developing and adult corneal epithelium. , 1993, Journal of cell science.
[101] M. Sliwkowski,et al. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.
[102] B. Olofsson,et al. Structure and expression of the chicken epidermal growth factor receptor gene locus. , 1986, European journal of biochemistry.
[103] S. Gygi,et al. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor , 2010, The Journal of cell biology.
[104] Pier Paolo Pandolfi,et al. Tenets of PTEN Tumor Suppression , 2008, Cell.
[105] H. Kato,et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. , 1996, European journal of cancer.
[106] J. Lammers,et al. Forkhead Transcription Factor FKHR-L1 Modulates Cytokine-Dependent Transcriptional Regulation of p27KIP1 , 2000, Molecular and Cellular Biology.
[107] Olle Stål,et al. Akt kinases in breast cancer and the results of adjuvant therapy , 2003, Breast Cancer Research.
[108] T. Joseph,et al. Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2. , 2001, Biochemical and biophysical research communications.
[109] Faye M. Johnson,et al. Regulation of Src Family Kinases in Human Cancers , 2011, Journal of signal transduction.
[110] J. Kuriyan,et al. Emerging concepts in the regulation of the EGF receptor and other receptor tyrosine kinases. , 2014, TIBS -Trends in Biochemical Sciences. Regular ed.
[111] Brian A. Hemmings,et al. Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 Binding , 2006, Molecular and Cellular Biology.
[112] O. Maertens,et al. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. , 2014, Advances in biological regulation.
[113] Yong Liao,et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.
[114] Kuo-Fen Lee,et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.
[115] P. Shapiro,et al. Cdc2-mediated Inhibition of Epidermal Growth Factor Activation of the Extracellular Signal-regulated Kinase Pathway during Mitosis* , 2005, Journal of Biological Chemistry.
[116] T. Pawson,et al. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1 , 1993, Nature.
[117] D A Lauffenburger,et al. Intracellular Trafficking of Epidermal Growth Factor Family Ligands Is Directly Influenced by the pH Sensitivity of the Receptor/Ligand Interaction (*) , 1995, The Journal of Biological Chemistry.
[118] T. Oyama,et al. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. , 2010, Anticancer research.
[119] Zhixiang Wang,et al. EGF stimulates the activation of EGF receptors and the selective activation of major signaling pathways during mitosis. , 2015, Cellular signalling.
[120] C. Rommel,et al. Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. , 1996, Oncogene.
[121] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[122] A. Johnson,et al. Activation of epidermal growth factor receptor gene transcription by phorbol 12-myristate 13-acetate is mediated by activator protein 2. , 1996, The Journal of biological chemistry.
[123] Hye-Nan Kim,et al. Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels. , 2012, International journal of oncology.
[124] Y. Choi,et al. The roles of phospholipase D in EGFR signaling. , 2009, Biochimica et biophysica acta.
[125] Hoyun Lee,et al. The Akt isoforms are present at distinct subcellular locations. , 2010, American journal of physiology. Cell physiology.
[126] K. Guan,et al. Positive and negative regulation of Raf kinase activity and function by phosphorylation , 2001, The EMBO journal.
[127] T. Hunter,et al. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine , 1980, Proceedings of the National Academy of Sciences.
[128] H. Kennecke,et al. Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer. , 2010, Current oncology.
[129] J. Schlessinger,et al. Activation of phospholipase Cγ by PI 3‐kinase‐induced PH domain‐mediated membrane targeting , 1998 .
[130] E. Lander,et al. Growth Factor-specific Signaling Pathway Stimulation and Gene Expression Mediated by ErbB Receptors* 210 , 2001, The Journal of Biological Chemistry.
[131] E. Carrasco-García,et al. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. , 2011, Experimental cell research.
[132] M. Wigler,et al. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. , 1993, Science.
[133] C. Marshall,et al. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells , 1994, Cell.
[134] Andrius Kazlauskas,et al. Growth-factor-dependent mitogenesis requires two distinct phases of signalling , 2001, Nature Cell Biology.
[135] G. M. Walton,et al. Structural analysis of the transmembrane domain of the epidermal growth factor receptor. , 1991, The Journal of biological chemistry.
[136] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[137] Nobuyoshi Shimizu,et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. , 2006, Cancer research.
[138] S. Ryu,et al. The phox homology domain of phospholipase D activates dynamin GTPase activity and accelerates EGFR endocytosis , 2006, Nature Cell Biology.
[139] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[140] M. Naujokas,et al. Identification of an Atypical Grb2 Carboxyl-terminal SH3 Domain Binding Site in Gab Docking Proteins Reveals Grb2-dependent and -independent Recruitment of Gab1 to Receptor Tyrosine Kinases* , 2000, The Journal of Biological Chemistry.
[141] J. Reid,et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[142] John D Potter,et al. Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer. , 2011, International journal of molecular epidemiology and genetics.
[143] R. McPherson,et al. 14-3-3 Facilitates Ras-Dependent Raf-1 Activation In Vitro and In Vivo , 1998, Molecular and Cellular Biology.
[144] A. Ullrich,et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells , 1987, Cell.
[145] A. Bass,et al. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma , 2017, Nature Communications.
[146] Sarat Chandarlapaty,et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.
[147] E. Reddy,et al. Signaling by dual specificity kinases , 1998, Oncogene.
[148] H. Kitano,et al. A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.
[149] D. Sabatini,et al. DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.
[150] K. Okazaki,et al. The Mos/MAP kinase pathway stabilizes c‐Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. , 1995, The EMBO journal.
[151] M. Greenberg,et al. Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.
[152] A. Wen,et al. Autophagy is a therapeutic target in anticancer drug resistance. , 2010, Biochimica et biophysica acta.
[153] B. Gusterson,et al. Cellular localisation of human epidermal growth factor receptor. , 1984, Cell biology international reports.
[154] M. Moran,et al. Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. , 1990, Science.
[155] Keegan S Johnson,et al. Persistent Corneal Epithelial Defect Associated With Erlotinib Treatment , 2009, Cornea.
[156] David R. Kaplan,et al. Direct Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate , 1997, Science.
[157] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[158] T. Pawson,et al. A conserved amino-terminal Shc domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides , 1995, Current Biology.
[159] M. Roussel,et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.
[160] Lewis C Cantley,et al. Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer. , 2016, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[161] A. Krasinskas. EGFR Signaling in Colorectal Carcinoma , 2011, Pathology research international.
[162] Jie Zhou,et al. Akt1 governs breast cancer progression in vivo , 2007, Proceedings of the National Academy of Sciences.
[163] S. Cohen,et al. The stimulation of epidermal keratinization by a protein isolated from the submaxillary gland of the mouse. , 1963, The Journal of investigative dermatology.
[164] A. Ullrich,et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling , 1992, Cell.
[165] Jonathan A. Cooper,et al. Tyr527 is phosphorylated in pp60c-src: implications for regulation. , 1986, Science.
[166] R. Erikson,et al. Avian sarcoma virus-transforming protein, pp60src shows protein kinase activity specific for tyrosine , 1980, Nature.
[167] C. Proud,et al. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1 , 2008, Oncogene.
[168] C. Grant,et al. The EGF receptor transmembrane domain: peptide-peptide interactions in fluid bilayer membranes. , 2000, Biophysical journal.
[169] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[170] Li Zhao,et al. Phosphatidylinositol 3-kinase: the oncoprotein. , 2010, Current topics in microbiology and immunology.
[171] P. Jänne,et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[172] B. Taylor,et al. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. , 2015, Cancer discovery.
[173] M. Birnbaum,et al. Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.
[174] K. Moelling,et al. Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.
[175] W. Kolch,et al. Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.
[176] Carlotta Costa,et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. , 2012, Cancer research.
[177] M. Lemmon,et al. Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor. , 2014, Cell reports.
[178] D. Alessi,et al. The nuts and bolts of AGC protein kinases , 2010, Nature Reviews Molecular Cell Biology.
[179] Matthew Meyerson,et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.
[180] A. Merlo,et al. Stabilization of Mdm2 via Decreased Ubiquitination Is Mediated by Protein Kinase B/Akt-dependent Phosphorylation* , 2004, Journal of Biological Chemistry.
[181] T. Pellinen,et al. Negative regulation of EGFR signalling through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP. , 2005, Nature cell biology.
[182] Holger Fröhlich,et al. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance , 2009, BMC Systems Biology.
[183] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.
[184] Ximing J. Yang,et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.
[185] M. Beckmann,et al. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. , 1999, The American journal of pathology.
[186] Zhixiang Wang,et al. Dimerization drives EGFR endocytosis through two sets of compatible endocytic codes , 2015, Journal of Cell Science.
[187] D. Riethmacher,et al. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor , 1997, Nature.
[188] G. Carpenter,et al. Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. , 1975, The Journal of biological chemistry.
[189] Jie Yang,et al. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib , 2013, Molecular oncology.
[190] Yoshikazu Nakamura,et al. Roles of phospholipase C isozymes in organogenesis and embryonic development. , 2009, Physiology.
[191] J. Slingerland,et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.
[192] M. Dimon,et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo , 2013, Proceedings of the National Academy of Sciences.
[193] Guang Peng,et al. Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response , 2015, Cell Research.
[194] T. Seufferlein,et al. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. , 1999, Cancer research.
[195] Y. Fukami,et al. c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. , 1995, Biochemical and biophysical research communications.
[196] D. Schuppan,et al. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. , 2005, Journal of hepatology.
[197] R. Kucherlapati,et al. Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[198] R. Breathnach,et al. Epidermal growth factor stimulates transcription of the c-jun proto-oncogene in rat fibroblasts , 1988, Nature.
[199] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[200] H. Hanafusa,et al. Comparative study of three protein-tyrosine phosphatases. Chicken protein-tyrosine phosphatase lambda dephosphorylates c-Src tyrosine 527. , 1994, The Journal of biological chemistry.
[201] B. Karlan,et al. FOXC1 is a Critical Mediator of EGFR Function in Human Basal-like Breast Cancer , 2014, Annals of Surgical Oncology.
[202] S. Ryu,et al. Direct interaction of SOS1 Ras exchange protein with the SH3 domain of phospholipase C-gamma1. , 2000, Biochemistry.
[203] B. Hemmings,et al. Life with a Single Isoform of Akt: Mice Lacking Akt2 and Akt3 Are Viable but Display Impaired Glucose Homeostasis and Growth Deficiencies , 2006, Molecular and Cellular Biology.
[204] James M. Roberts,et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. , 2003, Molecular cell.
[205] G. Carpenter,et al. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. , 1980, The Journal of biological chemistry.
[206] R. Roskoski. The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.
[207] M. Falasca,et al. Role of phospholipase C in cell invasion and metastasis. , 2013, Advances in biological regulation.
[208] D R Alessi,et al. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. , 1999, The Biochemical journal.
[209] L. Desjardins,et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. , 2014, European journal of cancer.
[210] A. Ciliberto,et al. Threshold-controlled ubiquitination of the EGFR directs receptor fate , 2013, The EMBO journal.
[211] S. R. Datta,et al. Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.
[212] John Kuriyan,et al. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.
[213] Brian A. Hemmings,et al. Protein Kinase Bα/Akt1 Regulates Placental Development and Fetal Growth* , 2003, Journal of Biological Chemistry.
[214] E. Lapetina,et al. Association of p21ras with phosphatidylinositol 3-kinase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[215] D. Hwang,et al. Phospholipase signalling networks in cancer , 2012, Nature Reviews Cancer.
[216] F. Gomez-Pinilla,et al. Epidermal growth factor receptor immunoreactivity in rat brain astrocytes. Response to injury , 1988, Neuroscience Letters.
[217] C. Rao,et al. Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta. , 1995, Endocrinology.
[218] O. Rath,et al. MAP kinase signalling pathways in cancer , 2007, Oncogene.
[219] M. Hung,et al. Mitosis-specific Negative Regulation of Epidermal Growth Factor Receptor, Triggered by a Decrease in Ligand Binding and Dimerization, Can Be Overcome by Overexpression of Receptor* , 1997, The Journal of Biological Chemistry.
[220] E. Krebs,et al. Human placenta protein-tyrosine-phosphatase: amino acid sequence and relationship to a family of receptor-like proteins. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[221] S. M. Rubin. Deciphering the retinoblastoma protein phosphorylation code. , 2013, Trends in biochemical sciences.
[222] B. Gusterson,et al. Increased EGF receptors on human squamous carcinoma cell lines. , 1986, British Journal of Cancer.
[223] R. Krumlauf,et al. Defects in pathfinding by cranial neural crest cells in mice lacking the neuregulin receptor ErbB4 , 2000, Nature Cell Biology.
[224] N. Tolwinski,et al. Epidermal Growth Factor Pathway Signaling in Drosophila Embryogenesis: Tools for Understanding Cancer , 2017, Cancers.
[225] M. Schaller,et al. Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654 , 2010, FEBS letters.
[226] Balazs Halmos,et al. EGFR-mutated lung cancer: a paradigm of molecular oncology , 2010, Oncotarget.
[227] Sheng-Chieh Hsu,et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.
[228] R. Weinberg,et al. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation , 1993, Nature.
[229] I. Gout,et al. The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.
[230] T M Jovin,et al. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation , 1995, The Journal of cell biology.
[231] R. Weinberg,et al. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. , 1994, Genes & development.
[232] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[233] T. Walz,et al. Mechanisms for Kinase-mediated Dimerization of the Epidermal Growth Factor Receptor* , 2012, The Journal of Biological Chemistry.
[234] Carlos L. Arteaga,et al. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.
[235] Agnieszka K. Witkiewicz,et al. The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.
[236] Y. Yarden,et al. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. , 1987, Biochemistry.
[237] Paul W. Sternberg,et al. The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily , 1990, Nature.
[238] S. Yokoyama,et al. Coassociation of Rap1A and Ha-Ras with Raf-1 N-terminal Region Interferes with Ras-dependent Activation of Raf-1* , 1997, The Journal of Biological Chemistry.
[239] A. King,et al. Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling , 1997, Molecular and cellular biology.
[240] B. Gusterson,et al. Evidence for increased epidermal growth factor receptors in human sarcomas , 1985, International journal of cancer.
[241] Z. Lu,et al. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[242] S. Parsons,et al. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[243] B. Liu,et al. Activation of epidermal growth factor receptors in astrocytes: From development to neural injury , 2007, Journal of neuroscience research.
[244] Miki Ebisuya,et al. Continuous ERK Activation Downregulates Antiproliferative Genes throughout G1 Phase to Allow Cell-Cycle Progression , 2006, Current Biology.
[245] G. Carpenter,et al. The Role of Individual SH2 Domains in Mediating Association of Phospholipase C-γ1 with the Activated EGF Receptor* , 1999, The Journal of Biological Chemistry.
[246] Joseph Avruch,et al. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity , 1998, Nature.
[247] M. Maa,et al. c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function* , 1999, The Journal of Biological Chemistry.
[248] Michael Chinkers,et al. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. , 1982, The Journal of biological chemistry.
[249] H. Kung,et al. Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[250] J. Qin,et al. Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding. , 2005, Molecular biology of the cell.
[251] B. Geiger,et al. Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency* , 1998, The Journal of Biological Chemistry.
[252] Richard D. Smith,et al. Network Analysis of Epidermal Growth Factor Signaling Using Integrated Genomic, Proteomic and Phosphorylation Data , 2012, PloS one.
[253] M. Karamouzis,et al. The molecular rationale of Src inhibition in colorectal carcinomas , 2014, International journal of cancer.
[254] R. Roskoski. ERK1/2 MAP kinases: structure, function, and regulation. , 2012, Pharmacological research.
[255] Jean J. Zhao,et al. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.
[256] Jonathan A. Cooper,et al. Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane , 1984, Nature.
[257] T Kendall Harden,et al. Mechanism of Phosphorylation-induced Activation of Phospholipase C-γ Isozymes*♦ , 2010, The Journal of Biological Chemistry.
[258] J. Parsons,et al. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation , 2003, The Journal of cell biology.
[259] B. Raught,et al. Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation , 2014, Proceedings of the National Academy of Sciences.
[260] Michael J. Fry,et al. Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.
[261] R. Medema,et al. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 , 2000, Nature.
[262] W. Cavenee,et al. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[263] Y. Yarden,et al. Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy , 2010, FEBS letters.
[264] S. Fields,et al. Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[265] F. De Vita,et al. Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy , 2009, Clinical and experimental immunology.
[266] M. Ohh,et al. New structural and functional insight into the regulation of Ras. , 2016, Seminars in cell & developmental biology.
[267] J. Altman,et al. Embryonic development of the rat cerebellum. I. Delineation of the cerebellar primordium and early cell movements , 1985, The Journal of comparative neurology.
[268] Edouard C. Nice,et al. Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis* , 2005, Journal of Biological Chemistry.
[269] E. Mayer. Targeting Breast Cancer with CDK Inhibitors , 2015, Current Oncology Reports.
[270] Ken-Ichi Sato. Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845 , 2013, International journal of molecular sciences.
[271] G. Mills,et al. Src Kinase Activity Is Regulated by the SHP-1 Protein-tyrosine Phosphatase* , 1997, The Journal of Biological Chemistry.
[272] M. C. Hu,et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. , 2000, The Journal of biological chemistry.
[273] M. Kawada,et al. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway , 1997, Oncogene.
[274] M. Monden,et al. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. , 2004, Oncology reports.
[275] I. Maruyama,et al. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells , 2008, Journal of Cell Science.
[276] B. Manning,et al. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. , 2008, The Biochemical journal.
[277] T. Curran,et al. Microinjection of transforming ras protein induces c-fos expression , 1987, Molecular and cellular biology.
[278] D. Orth,et al. Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[279] L. Cantley,et al. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[280] C. Asselin,et al. MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells. , 1999, American journal of physiology. Cell physiology.
[281] I. Pastan,et al. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. , 1987, Science.
[282] G. Shapiro,et al. A phase 1 study of ABT-806 in subjects with advanced solid tumors , 2015, Investigational New Drugs.
[283] Z. Werb,et al. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. , 1999, Development.
[284] W. Kolch,et al. Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation* , 2000, The Journal of Biological Chemistry.
[285] Y. Kido,et al. Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. , 1994, The Journal of biological chemistry.
[286] J. Farndon,et al. EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.
[287] Jonathan A. Cooper,et al. The Phosphorylation of Eukaryotic Initiation Factor eIF4E in Response to Phorbol Esters, Cell Stresses, and Cytokines Is Mediated by Distinct MAP Kinase Pathways* , 1998, The Journal of Biological Chemistry.
[288] D. Schneider,et al. Transmembrane helix-helix interactions involved in ErbB receptor signaling , 2010, Cell adhesion & migration.
[289] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.
[290] P. Parker,et al. Identification of the phosphorylated region responsible for the permissive activation of protein kinase C. , 1993, The Journal of biological chemistry.
[291] P. Graves,et al. 14-3-3 Proteins Are Required for Maintenance of Raf-1 Phosphorylation and Kinase Activity , 1998, Molecular and Cellular Biology.
[292] P. Libby,et al. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells , 1989, Cell.
[293] Nanxin Li,et al. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling , 1993, Nature.
[294] Walter Gilbert,et al. Ligands for ErbB-family receptors encoded by a neuregulin-like gene , 1997, Nature.
[295] J. Darbon,et al. The p42/p44 Mitogen-activated Protein Kinase Activation Triggers p27Kip1 Degradation Independently of CDK2/Cyclin E in NIH 3T3 Cells* , 2001, The Journal of Biological Chemistry.
[296] P. Cohen,et al. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. , 1993, The Biochemical journal.
[297] Hemant K Roy,et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. , 2002, Carcinogenesis.
[298] Kathryn G. Foster,et al. Site-Specific mTOR Phosphorylation Promotes mTORC1-Mediated Signaling and Cell Growth , 2009, Molecular and Cellular Biology.
[299] A. King,et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338 , 1998, Nature.
[300] A. Bardelli,et al. Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.
[301] J. Westermarck,et al. DNA Topoisomerase I Is a Cofactor for c-Jun in the Regulation of Epidermal Growth Factor Receptor Expression and Cancer Cell Proliferation , 2005, Molecular and Cellular Biology.
[302] M. Freeman,et al. Control of EGF receptor activation in Drosophila. , 1997, Trends in cell biology.
[303] F. Gomez-Pinilla,et al. Epidermal growth factor receptor immunoreactivity in rat brain. Development and cellular localization , 1988, Brain Research.
[304] J. Blenis,et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.
[305] K. Kinzler,et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[306] G. M. Walton,et al. Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. , 1990, The Journal of biological chemistry.
[307] Jonathan A. Cooper,et al. Mitogen‐activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 , 1997, The EMBO journal.
[308] A. Ullrich,et al. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high‐affinity binding site for SH2 domains of phospholipase C gamma. , 1992, The EMBO journal.
[309] J. Schlessinger,et al. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor , 1994, Molecular and cellular biology.
[310] S. Cohen,et al. Epidermal growth factor , 1972, The Journal of investigative dermatology.
[311] M. Birnbaum,et al. Akt/Protein Kinase B Isoforms Are Differentially Regulated by Epidermal Growth Factor Stimulation* , 2000, The Journal of Biological Chemistry.
[312] Martin Olbrot,et al. Characterization of Ser338 Phosphorylation for Raf-1 Activation* , 2008, Journal of Biological Chemistry.
[313] M. Hung,et al. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins , 2010, Oncogene.
[314] Z. Kam,et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.
[315] Zhixiang Wang,et al. Stimulation of Cell Proliferation by Endosomal Epidermal Growth Factor Receptor As Revealed through Two Distinct Phases of Signaling , 2003, Molecular and Cellular Biology.
[316] Y. Yarden,et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.
[317] Hyun-soo Cho,et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.
[318] A. Newton,et al. Suppression of survival signalling pathways by the phosphatase PHLPP , 2013, The FEBS journal.
[319] H. Koo,et al. Roles of AKT1 and AKT2 in non‐small cell lung cancer cell survival, growth, and migration , 2011, Cancer science.
[320] A. Newton,et al. Akt/Protein Kinase B Is Regulated by Autophosphorylation at the Hypothetical PDK-2 Site* , 2000, The Journal of Biological Chemistry.
[321] Sheila M. Thomas,et al. Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.
[322] G. Gibson,et al. Epidermal growth factor receptors in non-small cell lung cancer. , 1987, British Journal of Cancer.
[323] D. Morrison,et al. MAP kinase pathways. , 2012, Cold Spring Harbor perspectives in biology.
[324] P. Parker,et al. Threonine-497 is a critical site for permissive activation of protein kinase C alpha. , 1994, The Biochemical journal.
[325] S. Loi,et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. , 2013, Cancer treatment reviews.
[326] T. Tsuruo,et al. Akt/Protein Kinase B-Dependent Phosphorylation and Inactivation of WEE1Hu Promote Cell Cycle Progression at G2/M Transition , 2005, Molecular and Cellular Biology.
[327] S. Gabriel,et al. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.
[328] J. Schlessinger,et al. Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. , 1998, The EMBO journal.
[329] S. Cohen,et al. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. , 1962, The Journal of biological chemistry.
[330] Mengwei Zang,et al. Phosphorylation of 338SSYY341 Regulates Specific Interaction between Raf-1 and MEK1* , 2002, The Journal of Biological Chemistry.
[331] I. Dikic,et al. Cbl–CIN85–endophilin complex mediates ligand-induced downregulation of EGF receptors , 2002, Nature.
[332] H. Gan,et al. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered , 2013, The FEBS journal.
[333] L. Cantley,et al. Regulation of mTORC1 by PI3K signaling. , 2015, Trends in cell biology.
[334] A. Handyside,et al. EGF, TGF-alpha and EGFR expression in human preimplantation embryos. , 1995, Development.
[335] M. Andjelkovic,et al. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[336] H. Kim,et al. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. , 1994, The Journal of biological chemistry.
[337] L. Cantley,et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.
[338] M. Lacouture,et al. Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[339] M. Wiese,et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[340] S. Schreiber,et al. Grb2 SH3 binding to peptides from Sos: evaluation of a general model for SH3-ligand interactions. , 1995, Chemistry & biology.
[341] B. Wasylyk,et al. Ets ternary complex transcription factors. , 2004, Gene.
[342] M. Mann,et al. Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.
[343] T. Yamamoto,et al. CSK: a protein-tyrosine kinase involved in regulation of src family kinases. , 1991, The Journal of biological chemistry.
[344] R. Jayakumar,et al. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells. , 2014, Journal of biomedical nanotechnology.
[345] P. Allen,et al. Interaction of 14-3-3 with Signaling Proteins Is Mediated by the Recognition of Phosphoserine , 1996, Cell.
[346] Hongying Shen,et al. Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane , 2012, Proceedings of the National Academy of Sciences.
[347] C. Der,et al. Two Distinct Raf Domains Mediate Interaction with Ras (*) , 1995, The Journal of Biological Chemistry.
[348] T. van Dyke,et al. Akt-dependent Activation of mTORC1 Complex Involves Phosphorylation of mTOR (Mammalian Target of Rapamycin) by IκB Kinase α (IKKα)* , 2014, The Journal of Biological Chemistry.
[349] E. Lam,et al. Cell Cycle Inhibition by FoxO Forkhead Transcription Factors Involves Downregulation of Cyclin D , 2002, Molecular and Cellular Biology.
[350] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[351] K. Kinzler,et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. , 2004, The New England journal of medicine.
[352] J. Testa,et al. Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.
[353] Claudio R. Santos,et al. Lipid metabolism in cancer , 2012, The FEBS journal.
[354] H. Modjtahedi,et al. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. , 2009, Anti-cancer drugs.
[355] D. Laber,et al. Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers , 2009, Journal of oncology.
[356] J. Lakshmanan,et al. Metabolism and effects of epidermal growth factor and related growth factors in mammals. , 1990, Endocrine reviews.
[357] David J. Kwiatkowski,et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[358] J. Pouysségur,et al. ERK implication in cell cycle regulation. , 2007, Biochimica et biophysica acta.
[359] D. Bar-Sagi,et al. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos , 2007, Nature Cell Biology.
[360] J. Olefsky,et al. The signaling pathway coupling epidermal growth factor receptors to activation of p21ras. , 1994, The Journal of biological chemistry.
[361] M. Walter,et al. Regulation of FOXC1 Stability and Transcriptional Activity by an Epidermal Growth Factor-activated Mitogen-activated Protein Kinase Signaling Cascade* , 2006, Journal of Biological Chemistry.
[362] R. Seger,et al. The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions , 2006, Growth factors.
[363] J. Pouysségur,et al. Total ERK1/2 activity regulates cell proliferation , 2009, Cell cycle.
[364] R. Roth,et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[365] Toshiyuki Obata,et al. Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53* , 2002, The Journal of Biological Chemistry.
[366] Jodi Gureasko,et al. Membrane-dependent signal integration by the Ras activator Son of sevenless , 2008, Nature Structural &Molecular Biology.
[367] W. Russell,et al. Reversible G1 Arrest Induced by Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Requires Up-regulation of p27KIP1 Independent of MAPK Activity* , 2000, The Journal of Biological Chemistry.
[368] F. Ciccolini,et al. Prospective isolation of late development multipotent precursors whose migration is promoted by EGFR. , 2005, Developmental biology.
[369] B. Karlan,et al. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. , 2003, Cancer research.
[370] A. Paterson,et al. Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pubertal mammary duct development. , 1997, Molecular endocrinology.
[371] Zhixiang Wang,et al. Regulation of EGF‐Stimulated EGF Receptor Endocytosis During M Phase , 2011, Traffic.
[372] Michael J. Eck,et al. Three-dimensional structure of the tyrosine kinase c-Src , 1997, Nature.
[373] N. Shimizu,et al. Mapping of the human gene for epidermal growth factor receptor (EGFR) on the p13 leads to q22 region of chromosome 7. , 1983, Cytogenetics and cell genetics.
[374] B. Angus,et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. , 1995, Oncogene.
[375] C. Cartwright,et al. Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association. , 1995, Oncogene.
[376] Morag Park,et al. The Gab1 PH Domain Is Required for Localization of Gab1 at Sites of Cell-Cell Contact and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase , 1999, Molecular and Cellular Biology.
[377] R. Derynck,et al. Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. , 1991, Cell regulation.
[378] S. Gammeltoft,et al. 90-kDa Ribosomal S6 Kinase Is Phosphorylated and Activated by 3-Phosphoinositide-dependent Protein Kinase-1* , 1999, The Journal of Biological Chemistry.
[379] D. Rimm,et al. Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis , 2005, Clinical Cancer Research.
[380] D. W. Fry,et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.
[381] G. Superti-Furga,et al. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. , 1997, Journal of molecular biology.
[382] E. Nishida,et al. ERK MAP kinase in G1 cell cycle progression and cancer , 2006, Cancer science.
[383] J. Avruch,et al. An intact Raf zinc finger is required for optimal binding to processed Ras and for ras-dependent Raf activation in situ , 1997, Molecular and cellular biology.
[384] W. Pao,et al. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer , 2013, Proceedings of the National Academy of Sciences.
[385] Mads Lerdrup,et al. Differential Effects of EGFR Ligands on Endocytic Sorting of the Receptor , 2009, Traffic.
[386] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[387] N. Pryer,et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.
[388] Sandrine Roy,et al. Activity of Plasma Membrane-recruited Raf-1 Is Regulated by Ras via the Raf Zinc Finger* , 1997, The Journal of Biological Chemistry.
[389] G. Frantz,et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. , 1997, Development.
[390] Y. Zeng,et al. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. , 2001, Cancer letters.
[391] K. Guan,et al. Negative Regulation of the Forkhead Transcription Factor FKHR by Akt* , 1999, The Journal of Biological Chemistry.
[392] S. Collins,et al. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. , 2013, Cancer Research.
[393] T. Silhavy,et al. Genomic and Biochemical Insights into the Specificity of ETS Transcription Factors , 2017 .
[394] N. Shimizu,et al. Mapping of the human gene for epidermal growth factor receptor (EGFR) on the p13→q22 region of chromosome 7 , 1983 .
[395] F. McCormick,et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. , 1998, Science.
[396] S. Cohen,et al. The stimulation of epidermal proliferation by a specific protein (EGF). , 1965, Developmental biology.
[397] J. Downward,et al. Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation. , 1996, The EMBO journal.
[398] R. Marais,et al. S338 Phosphorylation of Raf-1 Is Independent of Phosphatidylinositol 3-Kinase and Pak3 , 2001, Molecular and Cellular Biology.
[399] Hye-Nan Kim,et al. Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels , 2011, International journal of oncology.
[400] M. Gassmann,et al. ErbB4 Signaling During Breast and Neural Development: Novel Genetic Models Reveal Unique ErbB4 Activities , 2003, Cell cycle.
[401] Y. Kido,et al. Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells. , 1998, Molecular endocrinology.
[402] C. Futter,et al. EGF receptor trafficking: consequences for signaling and cancer , 2014, Trends in cell biology.
[403] Zhimin Lu,et al. Phospholipase D and RalA Cooperate with the Epidermal Growth Factor Receptor To Transform 3Y1 Rat Fibroblasts , 2000, Molecular and Cellular Biology.
[404] G. Carpenter,et al. Essential role of the tyrosine kinase substrate phospholipase C-gamma1 in mammalian growth and development. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[405] Qinhua Zhou,et al. AG1478 inhibits the migration and invasion of cisplatin-resistant human lung adenocarcinoma cells via the cell cycle regulation by matrix metalloproteinase-9 , 2014, Oncology letters.
[406] Xuejun Jiang,et al. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. , 2003, Molecular biology of the cell.
[407] A. Newton,et al. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.
[408] Daoyuan Wang,et al. Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines. , 2013, Cancer biotherapy & radiopharmaceuticals.
[409] Mathew J Garnett,et al. Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.
[410] C. Porta,et al. Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..
[411] E. Nishida,et al. Dynamics of the Ras/ERK MAPK Cascade as Monitored by Fluorescent Probes* , 2006, Journal of Biological Chemistry.
[412] Derek Toomre,et al. Spatial control of EGF receptor activation by reversible dimerization on living cells , 2010, Nature.
[413] J. Rodríguez-Ubreva,et al. Distinct and specific roles of AKT1 and AKT2 in androgen-sensitive and androgen-independent prostate cancer cells. , 2013, Cellular signalling.
[414] C. Marshall,et al. Control of the ERK MAP kinase cascade by Ras and Raf. , 1996, Cancer surveys.
[415] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[416] S. Yokoyama,et al. Cysteine-rich Region of Raf-1 Interacts with Activator Domain of Post-translationally Modified Ha-Ras (*) , 1995, The Journal of Biological Chemistry.
[417] M. Shipitsin,et al. An EGF receptor/Ral‐GTPase signaling cascade regulates c‐Src activity and substrate specificity , 2000, The EMBO journal.
[418] H. Varmus,et al. The purified product of the transforming gene of avian sarcoma virus phosphorylates tyrosine. , 1980, The Journal of biological chemistry.
[419] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[420] V. Band,et al. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants# , 2009, Oncogene.
[421] S. Chandarlapaty,et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer , 2011, Oncogene.
[422] M. Hung,et al. RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus , 2010, Proceedings of the National Academy of Sciences.
[423] R. Scharpf,et al. The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.
[424] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[425] D. A. Foster,et al. Epidermal growth factor induces the production of biologically distinguishable diglyceride species from phosphatidylinositol and phosphatidylcholine via the independent activation of type C and type D phospholipases. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[426] A. Nielsen,et al. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. , 2016, Translational lung cancer research.
[427] L. Cantley,et al. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate , 1988, Nature.
[428] K. Makino,et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.
[429] Y. Yarden,et al. A mutant EGF‐receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling , 2002, The EMBO journal.
[430] Yong-soo Kim,et al. Bone Morphogenetic Protein 2 Inhibits Platelet-derived Growth Factor-induced c-fos Gene Transcription and DNA Synthesis in Mesangial Cells , 1999, The Journal of Biological Chemistry.
[431] M. Roussel,et al. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[432] G. Mann,et al. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[433] G. M. Walton,et al. Phosphorylation of the epidermal growth factor receptor at threonine 654 inhibits ligand-induced internalization and down-regulation. , 1990, Journal of Biological Chemistry.
[434] Ming Zhou,et al. Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.
[435] Stephan M. Winkler,et al. Quantification and Kinetic Analysis of Grb2-EGFR Interaction on Micro-Patterned Surfaces for the Characterization of EGFR-Modulating Substances , 2014, PloS one.
[436] C. Albanese,et al. Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.
[437] K. Hristova,et al. Receptor tyrosine kinase transmembrane domains , 2010, Cell adhesion & migration.
[438] Seo Yun Kim,et al. Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells , 2014, Cellular Oncology.
[439] W. Fantl,et al. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. , 1995, Science.
[440] L. Cantley,et al. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.
[441] Anita B. Roberts,et al. Autocrine growth factors and cancer , 1985, Nature.
[442] G. Mills,et al. Tyrosine Phosphorylation of p85 Relieves Its Inhibitory Activity on Phosphatidylinositol 3-Kinase* , 2001, The Journal of Biological Chemistry.
[443] D. Basketter,et al. Distribution and number of epidermal growth factor receptors in skin is related to epithelial cell growth. , 1983, Developmental biology.
[444] Chulhee Kim,et al. Block Copolymer Micelles Conjugated with anti-EGFR Antibody for Targeted Delivery of Anticancer Drug , 2008 .
[445] Robert J. Coffey,et al. EGF receptor ligands: recent advances , 2016, F1000Research.
[446] A. Fernández-Medarde,et al. Ras in cancer and developmental diseases. , 2011, Genes & cancer.
[447] W. Kolch,et al. Negative regulation of Raf-1 by phosphorylation of serine 621 , 1996, Molecular and cellular biology.
[448] Rüdiger Klein,et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.
[449] S. Grant,et al. A novel assay for the measurement of Raf-1 kinase activity , 2000, Oncogene.
[450] J. Ptak,et al. Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.
[451] P. Transidico,et al. Clathrin-independent endocytosis of ubiquitinated cargos. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[452] T. Ikeuchi,et al. The neurotrophic action and signalling of epidermal growth factor , 1997, Progress in Neurobiology.
[453] D. Cobrinik. Pocket proteins and cell cycle control , 2005, Oncogene.
[454] R. Harris,et al. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. , 2005, Cellular signalling.
[455] J. Kyte,et al. Dimerization of the Extracellular Domain of the Receptor for Epidermal Growth Factor Containing the Membrane-spanning Segment in Response to Treatment with Epidermal Growth Factor* , 1999, The Journal of Biological Chemistry.
[456] K. Shigematsu,et al. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. , 1990, Human pathology.
[457] P. Hawkins,et al. PI3K signalling: the path to discovery and understanding , 2012, Nature Reviews Molecular Cell Biology.
[458] Dhara N. Amin,et al. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. , 2012, The Biochemical journal.
[459] Y. Yarden,et al. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. , 1987, Biochemistry.
[460] Eric T. Kim,et al. Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization , 2012, Cell.
[461] Balazs Halmos,et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[462] M. Hung,et al. COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. , 2010, Biochemical and biophysical research communications.
[463] C. Arteaga,et al. Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers , 2009, Clinical Cancer Research.
[464] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[465] I. Pastan,et al. Epidermal growth factor receptor gene promoter. Deletion analysis and identification of nuclear protein binding sites. , 1988, The Journal of biological chemistry.
[466] P. Cohen,et al. A reinvestigation of the multisite phosphorylation of the transcription factor c‐Jun , 2003, The EMBO journal.
[467] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[468] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[469] A. Ullrich,et al. The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. , 1987, Oncogene research.
[470] Tony Hunter,et al. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.
[471] T. Frebourg,et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.
[472] M. Hung,et al. Nuclear EGFR is required for cisplatin resistance and DNA repair. , 2009, American journal of translational research.
[473] D. Wong,et al. Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 Upregulates p27KIP1 and p15INK4B and Induces G1 Arrest in Oral Squamous Carcinoma Cell Lines , 2002, Oncology.
[474] T. Deerinck,et al. Aberrant development of motor axons and neuromuscular synapses in erbB2-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[475] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[476] M. Pacher,et al. Dephosphorylation of Ser-259 Regulates Raf-1 Membrane Association* , 2002, The Journal of Biological Chemistry.
[477] P. Yue,et al. A Functional Nuclear Epidermal Growth Factor Receptor, Src and Stat3 Heteromeric Complex in Pancreatic Cancer Cells , 2011, PloS one.
[478] Y. Zhou,et al. NG 2 , a novel proapoptotic receptor , opposes integrin a 4 to mediate anoikis through PKC a-dependent suppression of FAK phosphorylation , 2008 .
[479] J. Blenis,et al. The RSK family of kinases: emerging roles in cellular signalling , 2008, Nature Reviews Molecular Cell Biology.
[480] M. Hung,et al. Nuclear‐cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1 , 2006, Journal of cellular biochemistry.
[481] R. Figlin,et al. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer , 1999, Journal of Cancer Research and Clinical Oncology.
[482] L. Cantley,et al. p120 Is a Cytosolic Adapter Protein That Associates with Phosphoinositide 3-Kinase in Response to Epidermal Growth Factor in PC12 and Other Cells (*) , 1996, The Journal of Biological Chemistry.
[483] S. Cohen,et al. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. , 1980, The Journal of biological chemistry.
[484] D. Morrison,et al. 14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3- and Ras-independent manner , 1995, Molecular and cellular biology.
[485] Silvia Benvenuti,et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.
[486] J. Cheng,et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[487] A. Brunet,et al. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. , 1994, Oncogene.
[488] Yan Liu,et al. The gift of Gab , 2002, FEBS letters.
[489] P. Harari,et al. Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.
[490] M. Hung,et al. HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.
[491] D. Hochhauser,et al. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. , 2011, Cancer research.
[492] B. Raught,et al. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis , 2015, Nature Communications.
[493] C. Der,et al. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.
[494] Giulio Superti‐Furga,et al. Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation , 1999, The EMBO journal.
[495] Mikhail V. Blagosklonny,et al. The Restriction Point of the Cell Cycle , 2002, Cell cycle.
[496] J. Stock,et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. , 2003, The Journal of clinical investigation.
[497] I. Reischl,et al. A New Tyrosine Phosphorylation Site in PLCγ1: The Role of Tyrosine 775 in Immune Receptor Signaling , 2005, The Journal of Immunology.
[498] Qing-quan Li,et al. EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells , 2011, Molecular Biology Reports.
[499] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.